Subgroup analysis from LITESPARK 011 revealed a significantly stronger benefit (hazard ratio 0.47) for the Belzutifan combination in favorable-risk patients. This supports the hypothesis that these tumors are more purely dependent on the HIF/VEGF pathway, suggesting an angiogenic signature could emerge as a predictive biomarker for Belzutifan's efficacy.

In the CAPITELLO-281 trial, PTEN-deficient patients receiving standard-of-care abiraterone had a median time to progression of about two years. This is shorter than expected for the general population, prospectively validating PTEN deficiency as a biomarker for a more aggressive disease phenotype with poor outcomes.

The AKT pathway, activated by PTEN loss, drives cancer growth independently of the androgen receptor, which controls PSA production. This discordance means clinicians cannot rely on PSA alone and must use systematic imaging to detect progression in this specific patient subgroup.

Data from the CAPItello trial showed a significant number of patients with PTEN deficiency experienced radiological progression without a corresponding PSA increase. This challenges the standard reliance on PSA for monitoring in high-risk prostate cancer and suggests a need for more frequent, personalized imaging protocols to detect progression earlier.

Experts believe molecular tests like Decipher and PTEN status are superior to simply counting bone lesions for guiding treatment. While not yet standard practice for all decisions, this represents a significant shift towards using underlying tumor biology to determine therapy, like adding docetaxel.

Using capivasertib in the hormone-sensitive setting is preferred because the cancer is more likely dependent on the AKT pathway for growth. In later, castration-resistant stages, additional genetic alterations can emerge, creating redundant growth signals and potentially diminishing the inhibitor's efficacy.

The panel suggests AKT inhibitor trials in prostate cancer have been disappointing due to suboptimal biomarker selection (e.g., PTEN IHC). A similar drug in breast cancer showed significant survival benefit when using a more precise NGS-based strategy, indicating a potential path forward if the right patient population is identified genetically.

Unlike androgen receptor mutations that arise under treatment pressure, PTEN loss is an earlier event. Therefore, tissue from an original biopsy or prostatectomy remains informative for testing PTEN status when a patient relapses with metastatic disease, simplifying the diagnostic process and avoiding invasive re-biopsies.

While seen early, even in low-grade cancers, PTEN loss is primarily associated with the cancer's progression to more aggressive forms. It correlates with transitions to higher grades, more advanced stages, and ultimately, metastatic states, marking it as a critical event in the disease's natural history.